The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

I believe that Merck (NYSE:MRK) is a good long-term pharmaceutical company to own and with that being said, it is because of several excellent moves it has made in the last few years. The first major ...

FDA approves Bravecto Quantum (fluralaner), the first annual injection against fleas and ticks in dogs, offering 12 months of ...

Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...

FDA has approved the new furosemide injection for treating edema in adults with chronic heart failure.Lasix ONYU was ...